Imide-Based Bifunctional Modulators for Cereblon-Directed Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing small molecule drugs face challenges in targeting protein-protein interactions, particularly with E3 ubiquitin ligases, which are attractive therapeutic targets due to their substrate specificity, but current ligands lack specificity and tunability for modulating a wide range of protein classes, hindering effective treatments for diseases like multiple myeloma and cancers.
Innovation Solution
Development of bifunctional imide-based compounds, known as PROTACs, that recruit endogenous proteins to E3 ubiquitin ligases for degradation, specifically utilizing a cereblon E3 ubiquitin ligase binding moiety (CLM) to target and degrade proteins of interest, enabling targeted ubiquitination and inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule drugs are used to target E3 ubiquitin ligases, then therapeutic potential is achieved, but specificity and tunability for different protein substrates are insufficient
Solution Approach 1:
The small molecule drug is segmented into two distinct functional moieties: a first moiety that binds to the E3 ubiquitin ligase and a second moiety that binds to the target protein substrate. This segmentation allows each moiety to independently optimize its binding specificity, thereby achieving both therapeutic reliability and substrate-specific adaptability simultaneously.
2Ease of operation
If small molecule drugs bind to E3 ligases, then protein-protein interactions are targeted, but the large contact surfaces and shallow grooves make targeting difficult
Solution Approach 1:
The bifunctional small molecule acts as an intermediary that bridges the E3 ubiquitin ligase and the target protein substrate. Rather than requiring direct binding between the small molecule and the complex protein-protein interaction interface, the intermediary small molecule facilitates the interaction by binding to both partners, thereby simplifying the targeting of large contact surfaces and shallow grooves.
3Reliability
If thalidomide and its analogs are used to bind cereblon, then multiple myeloma treatment is achieved, but lack of tunability limits application to other protein classes
Solution Approach 1:
The bifunctional small molecule design provides universality by enabling the same molecular framework to target multiple different protein substrates. By replacing the second moiety while retaining the first moiety that binds to cereblon or other E3 ligases, the system can be adapted to target various protein classes including transcription factors, receptors, and enzymes, thereby achieving both reliable anti-tumor activity and broad versatility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds provide a broad range of pharmacological activities, allowing for the specific degradation and inhibition of various proteins, effectively treating conditions such as large B-cell lymphoma, prostate cancer, ovarian cancer, breast cancer, multiple myeloma, uterine cancer, colon cancer, and leukemia by modulating protein levels.
Implementation Method 1
The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention.
Implementation Method 2
This complex ubiquitinates a number of other proteins. Through a mechanism which has not been completely elucidated, cereblon ubquitination of target proteins results in increased levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10).
Data Source
Figure 1(A)~1(B)
AI summary
The description relates to imide-based compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.